Online Medical Reference

Breast Disorders, Cancer Screening, and Risk Assessment

Holly J. Pederson, MD
Shazia Goraya, MD

Published: November 2019

Introduction

Breast health is an important health care concerns in the United States and worldwide. Health care services for women are often fragmented across multiple providers. Misunderstandings about breast health are common in the general population and even among health providers. Providers are often overwhelmed by complex insurance requirements and time constraints, thus it is imperative that primary care providers (PCPs), obstetricians/gynecologists (OB/GYNs), and other frontline providers have the tools and knowledge to accurately evaluate and diagnose breast disorders.

Back to Top

Prevalence

Breast cancer is the most common cancer in women and second only to lung cancer in cancer mortality among women in the United States with an estimated 268,600 new cases and 41,760 deaths in 2019.1 Breast cancer also occurs in men at a much lower incidence than women with an estimated 2,670 new cases and 500 deaths in men in 2019.1

Women in the U.S. have a 12.4 % (1 in 8) estimated lifetime risk for developing breast cancer, with a median age at diagnosis of 62 years.2 Breast cancer screening and treatment with hormonal therapy, chemotherapy, radiation therapy, and more recently, targeted therapy are increasing the survival rate of patients with breast cancer since 1990.1

Most breast health concerns are caused by benign breast disease (BBD). About 25% of women will present with a breast complaint during their lifetime. Among patients presenting with BBD, the majority (67%) were age 21 to 40.3 Pain, lump, and nipple discharge are common symptoms of BBD.

Back to Top

Pathophysiology

Most breast complaints are due to BBD or noncancerous disorders of the breast. Though not life threatening, some BBDs may increase the risk of breast cancer. BBD constitutes a diverse spectrum of lesions including developmental lesions, inflammatory lesions, neoplasms, and epithelial and stromal proliferative as well as nonproliferative disorders.

Histologically, BBD can be divided into 3 groups based on a classification system proposed by Dupont and Page:

  • Non-proliferative disorders – no increased risk of breast cancer (relative risk of cancer is 0.89­1 and 15-year absolute risk is 2%)
    • These include cysts, apocrine change, mild epithelial hyperplasia, ductal ectasia, non-sclerosing adenosis, and periductal fibrosis
  • Proliferative disorders without atypia – mild to moderate risk of breast cancer (relative risk of cancer is 1.3­1.9 and 15 year absolute risk is 4%)
    • These include usual ductal hyperplasia, sclerosing adenosis, radial scar, intraductal papilloma & papillomatosis, fibroadenoma, and pseudoangiomatous stromal hyperplasia
  • Proliferative disorders with atypia – high risk of breast cancer (relative risk of cancer is 3.9­13.0)
    • These include atypical ductal hyperplasia, atypical lobular hyperplasia and lobular carcinoma in situ.4

Fibrocystic changes (FCC) are the most common BBD and patients often present with pain, lumpiness, and nodularity. Over 50% of women will develop symptomatic FCC at some point in their lifetime. FCC appear to be hormonal in etiology. FCC is most prevalent in women age 20 to 59. Seldom do postmenopausal women experience symptomatic FCC unless they are on postmenopausal hormone replacement therapy.

Breast cysts range in size from 1 mm to several centimeters and are a common form of benign FCC and are usually unilocular within the breast. They are thought to arise as lobular lesions in which the terminal ductules dilate and unfold to enlarge as a cyst.

Ectopic breast or supernumerary breast tissue is the most common congenital/developmental abnormality of the breast.

A variety of inflammatory conditions can affect the breast. Some of these are from an infection, while others do not have a known etiology and may represent autoimmune processes and are classified as idiopathic.

Fibroadenoma is the most common benign breast neoplasm with a peak incidence at age 15 to 35. Lipoma of the breast is another typically solitary benign tumor composed of mature fat cells. Lactating adenoma is the most prevalent breast mass during pregnancy and puerperium. Hamartoma of the breast, also called fibroadenolipoma, is an uncommon benign tumor. Some cases have been related to a germline genetic mutation in patients with PTEN hamartoma tumor syndrome.

Back to Top

Risk Factors

Many risk factors for breast cancer have been identified (Table 1).5

Table 1: Factors in Women by Associated Relative Risk of Breast Cancer
Factors with a relative risk greater than 4.0
  • Age greater than 65 vs. less than 65
  • Atypical hyperplasia (confirmed by biopsy)
  • Inherited genetic mutations (BRCA1 or BRCA2 or both)
  • Ductal carcinoma in situ
  • Lobular carcinoma in site
  • Dense breast on mammography
  • History of early-onset (before age 40) breast cancer
  • 2 or more first-degree relatives diagnosed with early onset breast cancer
Factors with a relative risk 2.1 to 4.0
  • History of breast cancer at age 40 or later
  • High postmenopausal endogenous estrogen or testosterone levels
  • High-dose radiation to the chest
  • 1 first-degree relative with breast cancer
Factors with a relative risk 1.1 to 2.0
  • Positive margin on recent excision
  • Unexpected tumor involvement at lateral and/or deep edges after prior excision presumed to have been definitive.
  • Basal cell aggressive features
    1. Alcohol consumption
    2. Ashkenazi Jewish heritage
    3. Diethylstilbestrol exposure
    4. Early menarche (before age 12)
    5. Height (tall)
    6. High socioeconomic status
    7. Late age (over age 30) at first full-term pregnancy
    8. Late menopause (after age 55)
    9. Never breastfed
    10. No full-term pregnancies
    11. Obesity (postmenopausal/adult weight gain)
    12. History of endometrial or ovarian cancer
    13. Proliferative breast disease without atypia (usual ductal hyperplasia and fibroadenoma)
    14. Recent and long-term use of menopausal hormone therapy containing estrogen and progestin
    15. Recent oral contraceptive use

Data from reference 5

A hereditary predisposition to breast cancer also increases the risk of developing breast cancer at a younger age. Early identification of patients with a hereditary predisposition is imperative to take advantage of enhanced surveillance, chemoprevention, and risk reducing surgery. All women, especially black women and those of Ashkenazi Jewish descent, should be evaluated for the risk of breast cancer no later than age 30. Hallmark features of hereditary cancer are multiple cancers in an individual of family member(s), cancer at a young age, and rare cancers. Factors to identify individuals who should get tested for hereditary breast cancer are presented in Table 2.

Table 2: Individuals Who Should Get Tested for Hereditary Breast and Ovarian Cancer: “Rule of 1-2-3”
1 relativea: Diagnosis of 1 of the following in a patient, or a first- or second-degree relative:
  • Breast cancer at age 50 or younger
  • Ovarian cancer (any age)
  • Triple negative breast cancer before age 60
  • Male breast cancer (any age)
  • Metastatic prostate cancer
  • Patients of Ashkenazi descent with 1 breast, ovarian, pancreatic, or prostate cancer (any age)
  • Known carrier for breast cancer susceptibility gene mutation
2 member(s)a: Diagnosis of 2 cancers in a patient of a family member(s):
  • 2 primary breast cancers in the same individual with first diagnosed at or before age 50
  • Bilateral breast cancer (any age)
  • In patient of Ashkenazi descent, 1 breast, ovarian, pancreatic, or 2 prostate cancers (any age)
3 ageb: Diagnosis of 3 of these cancers in any combination on the same side of the family at any age:
  • Breast, ovarian, pancreatic, or prostate cancer

Adapted from the National Comprehensive Cancer Network6, American College of Obstetricians and Gynecologists7, U.S. Preventive Services Task Force8 and American Society of Breast Surgeons.9

aFirst-degree relatives include: parents, siblings and children; second-degree relatives include half-siblings, grandparents, aunts/uncles, nieces/nephews, and grandchildren

bIn this category only, third-degree relatives may be considered, which include first cousins, great-grandparents, great aunts/uncles, and great grandchildren

Mathematical models have been developed to quantitate the risk of breast cancer in women with no genetic predisposition. The most comprehensive model, which includes breast density, is the Tyrer – Cuzick model, or IBIS Breast Cancer Risk Evaluation Tool (http://www.ems-trials.org/riskevaluator/).

Many risk factors affect the lifetime exposure of breast tissue to hormones (early menarche, late menopause, obesity, and hormone use). Although exposures that influence risk accumulate throughout a woman’s life, research suggests that the time between menarche and first pregnancy may be particularly critical.10,11 About a third of post-menopausal breast cancers are thought to be caused by behavioral factors that are modifiable, such as postmenopausal obesity, physical inactivity, use of combined postmenopausal hormone therapy, alcohol consumption and not breastfeeding.12

Back to Top

Signs and Symptoms

Breast pain, lumps, and nipple discharge are the most common symptoms of BBD and breast cancer. Other possible symptoms include nipple inversion, skin changes (peau d’orange, ulcers, nipple excoriation, erythema, and scaling), swollen lymph nodes, and asymmetric thickening/nodularity.

Breast Pain

Breast pain (ie, mastalgia or mastodynia) is any discomfort or tenderness in the breast or underarm region. Onset, duration, relation to the menstrual cycle, current medications, and caffeine intake should be obtained.

Breast pain can be classified as cyclic or noncyclic. Cyclic pain is due to monthly hormonal changes and mostly occurs reproductive-age females. It generally ceases with pregnancy and menopause. Noncyclic pain is often isolated to 1 specific area of the breast and is the result of changes that occur in the milk ducts or milk glands, which can result in development of breast cysts.

Women can experience pain after breast injury, breast biopsy, or scar formation from prior breast surgery. Large pendulous breasts can also cause pain and so can a poorly fitted bra. FCC can cause pain and tenderness in the upper and outer quadrants of the breasts usually right before menses.

Some medications like oral birth control pills, postmenopausal hormone therapies, and infertility treatments may be associated with breast pain and tenderness.
Mastitis is an infection of the breast tissue that manifests as sudden onset of pain with local inflammation. Hidradentis suppurativa can manifest as painful breast nodules.

Chest wall pain, also known as extramammary breast pain, refers to pain that feels like it is coming from the breast, but actually is referred from elsewhere. It can be musculoskeletal pain or pain due to another medical condition like gallstones or cardiac ischemia. Costcohondritis or Tietze syndrome is an arthritic pain in the middle of the chest between the ribs and sternum. Patients are often very tender over the costochondral junctions on physical exam.

Pain can be the only presenting symptom of breast cancer in a small number of patients. Typically it is focal and sometimes there is an underlying mass or overlying skin erythema.

Breast Lumps

Most breast lumps result from benign conditions such as cysts or fibroadenomas. A breast lump can be a sign of breast cancer when it is firm or hard. Cancerous lumps can be irregular. Fixation to the chest wall or skin is a late finding of breast cancer. Cysts may be smooth and tender and fibroadenomas are often oval and slippery. Lumps cannot be accurately classified clinically. Discrete breast lumps warrant diagnostic evaluation. Nodularity related to FCC may be reported as a lump and may vary with the menstrual cycle. Any reported focal breast symptom should be thoroughly evaluated.

Lumps associated with nipple changes such as nipple inversion or nipple discharge are more suspicious for malignancy.

Nipple Discharge

Abnormal nipple discharge may be described as any discharge not associated with lactation and pregnancy.

Purulent discharge may be caused by mastitis or breast abscess. Milky discharge can occur with certain psychotropic medications and endocrine disorders such as hypothyroidism or prolactinoma. Milky discharge after breast-feeding can continue for up to 2 to 3 years after stopping nursing. Non-milky nipple discharge may be thick, sticky, greenish/black, clear, colorless, serous, sanguineous, serosanguineous, or bloody.

Pathologic discharge requiring diagnostic evaluation (diagnostic imaging and retroareolar ultrasound) is that which is spontaneous, bloody, clear or serosanguinous. It is most often unilateral and elicited from one duct. Pathologic nipple discharge is most commonly caused by a benign intraductal papilloma, but can also be a sign of ductal carcinoma in situ (DCIS) or invasive cancer.

Other possible causes of benign or physiologic nipple discharge include medications, FCC, excessive breast stimulation, mammary duct ectasia and periductal mastitis. Mammary duct ectasia, common in smokers, presents with greenish-black, creamy, yellowish or oily discharge from multiple ducts that is elicitable on examination but not typically spontaneous.

Drugs that can cause nipple discharge include psychoactive drugs, opiates, antihypertensive drugs, oral contraceptives, and estrogen.

Nipple discharge in men warrants urgent evaluation as this is a common presentation of breast cancer in men.

Back to Top

Diagnosis

Women should be familiar with their breast tissue (breast self-awareness) and should report any changes to their health care provider. In premenopausal women, breast self-exam is most informative when done at the end of menses.

Comprehensive clinical examination in conjunction with history, use of diagnostic imaging, targeted breast ultrasound, breast magnetic resonance imaging, and core needle biopsy (vacuum assisted) can facilitate timely diagnosis and management of breast disorders.

History

A detailed history is the cornerstone of diagnostic evaluation of breast symptoms. Reproductive history, results of prior biopsies, prior treatments, and a thorough family history should be ascertained.

Physical Examination

There is overall consensus that clinical breast examination (CBE) is a useful screening tool. The rationale for recommending a clinical encounter is to maximize the earliest detection of breast cancer.

The National Comprehensive Cancer Network Breast Cancer Screening and Diagnostic Guidelines Panel has concluded that in the absence of new evidence to suggest a lack of benefit or significant harm associated with CBE, CBE should be performed every 1 to 3 years for average-risk women aged 25 to 39 years and annually beginning at age 40 years.13 A systematic review of breast cancer screening found no benefit with the addition of CBE with mammography.14

A comprehensive breast examination should include inspection and palpation of the entire chest wall in upright and supine positions, extending up to the clavicle and neck, into the axilla, over the central chest and under the breast onto the rib cage. The clinician should note any lumps, asymmetry, nipple changes, or skin erythema or dimpling. Examination of the supraclavicular, infraclavicular, and axillary lymph nodes should follow the breast inspection. The presence of lymphadenopathy should prompt referral to a breast specialist, although the significance of shotty nodes is unclear. The characteristics of any breast lump is important. The breasts should then be palpated for thickening, nodularity, and detection of masses. Hard or irregular discrete masses suggest malignancy. The patient’s ipsilateral hand should be brought up to the head level for examination of the lateral part of the breast and the elbow should be at the shoulder level for examination of the breast. Palpation under the areola and a gentle squeeze of the nipple to elicit discharge is important.

Diagnostic Evaluation for Symptomatic Findings on Physical Examination

Symptomatic or positive findings on physical examination include a palpable mass in the breast, nipple discharge, asymmetric thickening or nodularity, skin changes, and breast pain. Clinical judgment should always be an important component of the optimal management of the patient.

In addition to the traditional craniocaudal and mediolateral oblique mammographic views, diagnostic imaging often includes spot tangential or magnification views per the radiologist’s recommendation, and targeted breast ultrasound. Diagnostic digital breast tomosynthesis is also sometimes employed, particularly to evaluate areas of architectural distortion.

Mammography utilizes very low-energy X-rays (around 30 kVp) to examine breast tissue and is both a diagnostic and a screening tool. Mammography has a false-negative rate of at least 10%. It is an error to rely on negative mammography results when there is a clinically suspicious mass. In such cases, negative findings should not preclude referral to a breast specialist.

Palpable Mass

A palpable mass is a discrete lesion that can be readily identified during a physical exam. For women under the age of 30, workup for a palpable mass begins with a targeted breast ultrasound; for women 30 and older, bilateral diagnostic imaging with a targeted breast ultrasound. Negative imaging results place a patient at a very low risk of malignancy (generally less than 3%); however, clinical judgment is necessary as some women with negative imaging may warrant biopsy and may have breast cancer.

Asymmetric thickening or nodularity is often vague on physical exam and imaging evaluation for it is the same as for a palpable mass.

Nipple Discharge

Nipple discharge is common and often unrelated to breast pathology. Suspicion of underlying pathology (eg, papilloma or malignancy) is raised when nipple discharge is persistent and reproducible on examination, spontaneous, unilateral, from a single duct, serous, sanguineous or serosanguinous. Workup of suspected pathologic nipple discharge begins with diagnostic imaging and a targeted retroareolar ultrasound. If negative, diagnostic breast magnetic resonance imaging (MRI) is a very valuable additional diagnostic tool. A negative MRI in this symptomatic population may obviate the need for duct exploration and excision.15 Ductography is sometimes employed to localize lesions.

Skin Changes

Inflammatory breast cancer should be considered when dermal edema (peau d’orange) and breast erythema are present. Nipple excoriation, scaling, and erythema should increase clinical suspicion for Paget’s disease. The initial evaluation begins with a bilateral diagnostic mammogram with or without ultrasound. If imaging is negative, punch biopsy should be performed. Antibiotics may or may not be given, depending on the clinical suspicion for breast infection, but should not delay diagnostic evaluation. Referral to a breast specialist should be considered early.

Breast Pain

Breast pain is very common and is rarely the only symptom of a malignancy. If pain is focal and persistent, age appropriate diagnostic imaging (bilateral diagnostic imaging with targeted ultrasound if 30 or older and targeted ultrasound if under 30) is recommended.

Breast Biopsy

Breast biopsy is routinely performed for diagnosis of suspicious areas of concern detected clinically or with mammography or sonography. A biopsy is the only diagnostic procedure that can definitely determine if the area of concern is benign or malignant. The majority of breast biopsies performed in United States are benign.

When an entire lump or suspicious area is removed, the procedure is called excisional biopsy. An incisional biopsy or core biopsy removes a portion of the abnormal tissue and is preferred over excisional biopsy.

Core biopsy is generally performed under imaging guidance (eg, stereotactic [mammographic], ultrasound or MRI) and involves a large-bore cutting needle to remove multiple cores of tissue. Punch biopsy of skin or nipple biopsy can help when there is a clinical suspicion of inflammatory breast cancer or Paget’s disease of the nipple.

Back to Top

Treatment of Common Breast Disorders

Breast Pain

Treatment for breast pain relies on an accurate diagnosis and is aimed at symptomatic relief and patient education. Most recommendations for treatment of breast pain are based on data from observational or case controlled studies, with minimal data from randomized controlled trials.

Antibiotics and surgical drainage are required for infections and some abscesses. Therapeutic aspiration can be performed for symptomatic breast cysts. Treatment of pain associated with FCC is not well studied. A well-fitted, supportive bra may be helpful. Some patients note relief with avoidance of caffeine.

Breast reduction mammoplasty may be helpful for those with large pendulous breasts and resultant pain.

Oral analgesics like acetaminophen or a nonsteroidal anti-inflammatory medications can sometimes relieve breast pain. Topical analgesics such as over the counter salicylate cream (Aspercreme) or prescription diclofenac gel (Voltarin) for local pain can be used on intact skin. Another often helpful remedy is evening primrose oil (2000 mg to 4000 mg/day in split doses).

Danazol reduces estrogen production and levels and is the only medication approved by the U.S. Food and Drug Administration for treatment of breast pain. Though effective is use is limited by androgenic side effects including weight gain, acne, hirsutism, and amenorrhea.

Tamoxifen may be beneficial for some patients with severe breast pain. Side effects including hot flashes and night sweats are relatively common, and there is an increased risk of venous thromboembolism associated with its use. Hence it is seldom used for this indication, but may be helpful in refractory cases.

Breast Lumps

Treatment depends on the diagnosis. Benign lumps should be followed clinically, for 1 to 2 years to assess for stability.13

Nipple Discharge

Nipple stimulation can sometimes cause nipple discharge and cessation will relieve the symptoms. Nipple discharge due to medication use (phenothiazines, selective serotonin reuptake inhibitors, oral contraceptives) warrants consideration of change in the medication. Medical or surgical therapy may be warranted if a prolactinoma is identified. Duct exploration and excision is sometimes required for diagnosis and treatment of pathologic nipple discharge, though a negative breast MRI currently may obviate the need for surgical intervention.15

Back to Top

Screening

Breast screening is performed in women without any signs or symptoms of breast. Women should be counseled about the potential benefits (including mortality reduction), risks, and limitations of breast screening.

The components of a breast screening evaluation depend on factors such as age and medical and family history. Breast screening may include breast awareness (ie, patient familiarity with her breasts and family history), physical examination, risk assessment, screening mammography and in some cases, screening breast MRI.

All women should be counseled to report any breast changes to their healthcare providers. Periodic, consistent breast self-examination may facilitate breast self-awareness. Accurate, regularly updated family history information is needed to adequately assess a woman’s individual breast cancer risk and to identify families with a hereditary predisposition.

Mammography

The goal of screening using mammography is the early detection of breast cancer typically through detecting masses or microcalcifications. Breast cancer mortality is reduced by at least 20% by regular screening mammography as demonstrated by randomized controlled trials.16-19 The overall sensitivity of screening mammography is approximately 75%.17 A diagnostic evaluation is used to evaluate an existing symptom or a clinical finding.

Patients of Average Risk

For women at average risk (Table 3), the age to begin mammography screening and the frequency of recommended screenings are controversial.13,16,20

Table 3: Characteristics of Women at Average Risk for Breast Cancer
Absence of a personal history of:
  • breast, ovarian or pancreatic cancer
  • a breast biopsy showing lobular cancer in situ, atypical ductal hyperplasia, atypical lobular hyperplasia or flat epithelial atypia
  • radiation therapy to the chest at or before age 30
Absence of a family history of:
  • Breast cancer
    • male breast cancer at any age
    • early onset breast cancer (diagnosed at or before age 50)
    • 2 or more breast primaries in a single relative at any age
    • triple negative breast cancer
  • Ovarian cancer at any age
  • Early onset pancreatic cancer (diagnosed at or before 50)
  • Metastatic prostate cancer
Absence of Ashkenazi Jewish ancestry
Absence of an identified high- or moderate-penetrance genetic predisposition (eg, breast cancer gene [BRCA] 1 or BRCA2 mutation) in the patient or in a first-, second-, or third-degree relative  

Cleveland Clinic has proposed recommendation for screening of women of average risk (Table 4) (Cleveland Clinic Care Path):

Table 4: Cleveland Clinic Recommended Screening for Women of Average Risk for Breast Cancer
Age Mammography Clinical Breast Exam
20–39 Not recommended Include with complete physical exam by primary care provider  
40–44 Every woman should have opportunity for an annual screening mammogram; shared decision making with primary care provider strongly recommended Include with complete physical exam by primary care provider
45–55 An annual screening mammogram recommended Include with complete physical exam by primary care provider
55 and older Screening mammograms recommended; shared decision-making with provider recommended to determine frequency (annual or every 2 years) Include with complete physical exam by primary care provider
Upper age limit: Less than 10 years remaining in expected life span If patient is in good health and is a reasonable candidate for treatment, mammogram is recommended; shared decision-making with provider recommended to determine frequency. Include with complete physical exam by primary care provider

Digital Breast Tomosynthesis

The use of digital mammography (2-dimensional [2D]) in conjunction with digital breast tomosynthesis (DBT) appears to improve cancer detection and reduce false-positive call-back rates.21-24 DBT allows acquisition of three-dimensional data which are reconstructed using computer algorithms. The combined use of 2D and DBT results in double the radiation exposure compared with digital mammography alone. However, this increase in radiation dose falls below dose limits of radiation set by the U.S. Food and drug Administration for standard mammography. It adds to the sensitivity of screening mammography in women at all levels of breast density.25

The presence of dense breast tissue decreases the sensitivity of screening mammography and is increasingly recognized as an important risk factor for breast cancer.26 According to American College of Radiology Breast Imaging Reporting and Data System, breast density is categorized as fatty, scattered fibroglandular, heterogeneously dense, or extremely dense. Thirty states in the U.S. now require that breast density information be reported to patients and most states encourage patients to discuss their breast density with their health care providers.27 Dense breasts limit the sensitivity of the mammography and extremely dense breast tissue is associated with an increased risk for breast cancer.26

About half of all women of screening age have “dense” breast tissue (heterogeneously dense or extremely dense as categorized by the American College of Radiology Breast Imaging Reporting and Data System nomenclature). There is currently insufficient evidence to support routine universal supplemental screening in women with dense breasts and no other risk factors.

Other Imaging Modalities

There is emerging evidence that breast scintigraphy (molecular breast imaging) may improve detection of early breast cancers among women with dense breasts, but is time intensive and associated with higher doses of radiation than standard digital mammography.

Mammography supplemented with breast ultrasound has been studied as a potential solution for screening of women with dense breasts as early detection of invasive cancers is improved with the 2 modalities over mammography alone. Screening breast ultrasounds are not available universally and require highly trained personnel. Breast ultrasonography does not detect microcalcifications, however, and is associated with a high false positive rate28 and is therefore not commonly recommended.

Current evidence does not support the routine use of thermography or ductal lavage as screening procedures.

Patients of High Risk

Annual MRI screening by a breast specialist is recommended for individuals at high risk, which is defined as meeting any of the following criteria:

  • Individuals with an identified BRCA mutation
  • Untested first-degree relatives (parents, siblings, children) of a known BRCA mutation carrier
  • Women with a lifetime risk of breast cancer of > 20% based on risk prediction models (eg, Gail model, Claus model, Tyrer-Cuzick model)
  • Women who received prior thoracic radiation (ie, mantle radiation) to the chest between 10 and 30 years of age
  • Women with other genetic mutations that increase the risk of breast cancer (eg, Li-Fraumeni syndrome, Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome) and their untested first-degree relatives
  • Women with a personal history of breast cancer and dense tissue or those diagnosed by age 50.29,30

Screening Breast MRI

Contrast-enhanced breast MRI has shown substantial promise in the early detection of breast cancer. The available literature suggests that the sensitivity of contrast enhanced breast MRI in detection of cancer is considerably higher than that of either mammography or ultrasound and is generally reported to be in excess of 96 %.31-39 It, however is not as specific, resulting in a higher rate of false positive findings as compared to digital mammography. In all tissue densities, contrast enhanced MRI is far better than mammography in detecting breast cancer, but the use of MRI is limited by high cost, patient tolerance, and availability. Of note is that microcalcifications and architectural distortion are not detectable with MRI; thus digital mammography or digital breast tomosynthesis remains as a screening modality recommendation in conjunction with screening breast MRI for those at elevated risk.

Research is being conducted to further validate using shortened screening MRI times (so called “abbreviated” or “fast” MRI) and hence lower cost and make the test available to more patients for supplemental screening.40

When to Stop Screening

Breast screening of patients over age 75 should be based on individual factors considering the benefits, risks, comorbidities, and life expectancy. Screening every other year is an option for women of average risk age 75 or older and can continue as long as expectancy is 10 years or greater.

Back to Top

Summary

  • Risk assessment begins with a careful personal and family history to identify patients at risk for hereditary cancer syndromes.
  • All women should be evaluated for breast cancer risk no later than age 30, with family history updated and reconsidered annually.
  • Mathematical models such as the Tyrer-Cuzick model can help identify patients at increased risk for which enhanced surveillance with annual MRI or chemoprevention discussions may be appropriate.
  • Modifiable risk factors for all patients include achieving and maintaining ideal body weight, regular physical activity, breastfeeding, limiting alcohol consumption, and limiting long term use of combined post-menopausal hormone therapy.
  • Age at initiation and frequency of mammographic screening should be a topic of shared decision making between the patient and provider, carefully discussing mortality reduction, risks and benefits.
  • Increased breast density is common. Digital breast tomosynthesis can be considered for enhanced sensitivity and specificity in women with dense tissue or in those at increased risk.
  • National Comprehensive Cancer Network diagnostic guidelines give health care providers a practical, consistent framework for screening and evaluating a spectrum of clinical breast symptoms and findings.

Back to Top

References

  1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.
  2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. Bethesda, MD: National Cancer Institute, 2017.
  3. Karki OB KDaDA. Benign Breast Diseases: Profile at a Teaching Hospital. Am J of Public Health Res 2015; 3:83–86.
  4. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
  5. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017.
  6. NCCN Guidelines Version 1.2018 Genetic/Familial Risk Assessment: Breast and Ovarian. 2018.
  7. Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol 2017; 130(3):e110-e26. doi: 10.1097/AOG.0000000000002296
  8. Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160(4):271–281. doi: 10.7326/M13-2568
  9. The American Society of Breast Surgeons website. Consensus guideline on genetic testing for hereditary breast cancer. Feb 2019 https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf Surgeons TASoB. The American Society of Breast Surgeons Consensus Statement: Hereditary Genetic Testing for Patients with and without Breast Cancer. March 14, 2017.
  10. Dall GV, Britt KL. Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front Oncol 2017; 7:110. doi: 10.3389/fonc.2017.00110
  11. Liu Y, Nguyen N, Colditz GA. Links between alcohol consumption and breast cancer: a look at the evidence. Womens Health (Lond) 2015; 11(1):65–77. doi: 10.2217/whe.14.62
  12. Tamimi RM, Spiegelman D, Smith-Warner SA, et al. Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am J Epidemiol 2016; 184(12):884–893.
  13. Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compre Canc Netw 2018; 16(11):1362-1389. doi: 10.6004/jnccn.2018.0083
  14. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: A systematic review. JAMA 2015; 314(15):1615–1634. doi: 10.1001/jama.2015.13183
  15. Bahl M, Baker JA, Greenup RA, Ghate SV. Evaluation of pathologic nipple discharge: What is the added diagnostic value of MRI? Ann Surg Oncol 2015; 22(Suppl 3):S435–S441. doi: 10.1245/s10434-015-4792-9
  16. Oeffinger KC, Fontham ET, Etzioni R, et al; American Cance Society. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 2015; 314(15):1599–1614. doi: 10.1001/jama.2015.12783
  17. Stout NK, Lee SJ, Schechter CB, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst 2014; 106(6):dju092. doi: 10.1093/jnci/dju092
  18. Webb ML, Cady B, Michaelson JS, et al. A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened. Cancer 2014; 120(18):2839–2846. doi: 10.1002/cncr.28199
  19. Helvie MA, Chang JT, Hendrick RE, Banerjee M. Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer. Cancer 2014; 120(17):2649–2656. doi: 10.1002/cncr.28784
  20. Siu AL, Force USPST. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016;164:279-96.
  21. Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): A prospective comparison study. Lancet Oncol 2013; 14(7):583–589. doi: 10.1016/S1470-2045(13)70134-7
  22. Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 2013; 267(1):47–56. doi: 10.1148/radiol.12121373
  23. Rafferty EA, Park JM, Philpotts LE, et al. Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial. Radiology 2013; 266(1):104–113. doi: 10.1148/radiol.12120674
  24. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 2014; 311(24):2499–2507. doi: 10.1001/jama.2014.6095
  25. Gilbert FJ, Tucker L, Gillan MG, et al. Accuracy of digital breast tomosynthesis for depicting breast cancer subgroups in a UK retrospective reading study (TOMMY Trial). Radiology 2015; 277(3):697–706. doi: 10.1148/radiol.2015142566
  26. Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K; Breast Cancer Surveillance Consortium. Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 2017; 3(9):1228–1236. doi: 10.1001/jamaoncol.2016.6326
  27. Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016; 164(4):268–278. doi: 10.7326/M15-1789
  28. Berg WA, Zhang Z, Lehrer D, et al; ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012; 307(13):1394–1404. doi: 10.1001/jama.2012.388
  29. Saslow D, Boetes C, Burke W, et al; American Cancer Society Breast Cancer Advisory Board. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57(2):75–89. PMID: 17392385
  30. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast cancer screening in women at higher-than-average risk: Recommendations from the ACR. J Am Coll Radiol 2018; 15(3 Pt A):408–414. doi: 10.1016/j.jacr.2017.11.034
  31. Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S. Supplemental breast MR imaging screening of women with average risk of breast cancer. Radiology 2017; 283(2):361–370. doi: 10.1148/radiol.2016161444
  32. Panigrahi B, Mullen L, Falomo E, Panigrahi B, Harvey S. An abbreviated protocol for high-risk screening breast magnetic resonance imaging: Impact on performance metrics and BI-RADS assessment. Acad Radiol 2017; 24(9):1132–1138. doi: 10.1016/j.acra.2017.03.014
  33. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012; 107(1):24–30. doi: 10.1038/bjc.2012.204
  34. Lehman CD, Blume JD, Weatherall P, et al; International Breast MRI Consortium Working Group. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103(9):1898–1905. PMID: 15800894
  35. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23(33):8469–8476. PMID: 16293877
  36. Kriege M, Brekelmans CT, Boetes C, et al; Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351(5):427–437. PMID: 15282350
  37. Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 2008; 246(1):116–124. PMID: 18024435
  38. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: The EVA trial. J Clin Oncol 2010; 28(9):1450–1457. doi: 10.1200/JCO.2009.23.0839
  39. Sardanelli F, Podo F, Santoro F, et al; High Breast Cance Risk Italian 1 (HIBCRIT-1) Study. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): Final results. Invest Radiol 2011; 46(2):94–105. doi: 10.1097/RLI.0b013e3181f3fcdf
  40. Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): First postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol 2014; 32(22):2304–2310. doi: 10.1200/JCO.2013.52.5386

Back to Top

 


 

Related CME Activities

Cleveland Clinic Florida’s 3rd Annual The Best of San Antonio Breast Cancer Symposium (SABCS®)
Jan 18, 2020 – Hollywood, FL

Breast Cancer Update: Review of Breast Cancer Symposia
Feb 12, 2020 – Independence, OH